WebFeb 1, 2024 · Thetis plans to investigate TP-317, an innovative and potential first in-class therapeutic agent, as a therapy for the treatment of eosinophilic esophagitis (EoE), a chronic, atopic disease characteri... WebDec 11, 2024 · TP-317 delivers Resolvin E1, ... The Thetis technology offers the possibility of applying the known pro-resolving activity of endogenous lipids for treatment of IBD. ...
Development of TP-317 for the Induction and Maintenance of …
WebRIDGEFIELD, CT AND NEW YORK, NY – (April 4, 2024) – Thetis Pharmaceuticals (“Thetis”), a pioneering therapeutics biotechnology company developing a first-in-class small molecule … WebCOVID-19 ARDS patients, there remains a significant unmet need for safe and effective therapies.Thetis Pharmaceuticals seeks to address the need for an effective treatment for ARDS through development of TP-317, a patent-protected salt of Resolvin E1, an endogenous lipid mediator that affects multiple mechanisms implicated in ARDS. railway tourism
Development of TP-317 for the Induction and Maintenance of …
WebThetis receives funding for IBD therapy. Thetis Pharmaceuticals has received funding from the Crohn’s & Colitis Foundation’s IBD Ventures program to support development of TP-317, a first-in-class, oral therapy for inflammatory bowel disease.. The active agent in TP-317 is Resolvin E1, an endogenous immuno-resolvent. “Resolvin E1 is a potent bioactive lipid … WebJul 28, 2024 · RIDGEFIELD, CT – Thetis Pharmaceuticals (“Thetis”), a leading developer of Resolvin-based therapies for cancer and autoimmune diseases, announced today that the … WebJan 20, 2024 · TP-317 is a first-in-class small molecule oral therapy in development for ulcerative colitis and Crohn’s Disease. RIDGEFIELD, CT – (January 20, 2024) – Thetis … railway tours